Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 08, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 525,000 ordinary shares of 25 pence each.
- Purchase Price: 1,423.0032 pence per share.
- Treasury Shares Held: 187,906,678 shares (post-transaction).
- Shares in Issue: 5,796,514,117 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 525,000 shares on August 08, 2006, increasing its Treasury shareholding. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 525,000 shares purchased at 1,423.0032 pence per share.
- Confirm the updated total number of shares in issue (5,796,514,117) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share repurchase authority.
- Check for subsequent Form 6-K filings to track further Treasury share movements.